# Maestro: robot model

Canonical ID: `d1fd6d55-bf1a-45e2-9612-d40019d2d867`

- **Slug:** moon-maestro
- **Form factor:** surgical
- **Maturity stage:** commercial
- **Lifecycle:** active
- **Deployments registered:** 0

## Specs

- **notes:** [object Object],[object Object],[object Object],[object Object]
- **products:** Maestro: a laparoscopic surgical-assistant platform (holds/positions instruments + endoscope alongside the surgeon). ScoPilot: shipped AI software (NVIDIA Holoscan-powered) for intraoperative scope control. Commercial Maestro FDA 510(k) K240598 cleared Jun 5 2024; ScoPilot FDA-cleared 2025 with a Predetermined Change Control Plan (PCCP).
- **formFactor:** surgical (laparoscopic surgical-assistant / collaboration robot: holds + positions instruments alongside the surgeon; not full master-slave teleop)

## Deployments

_No deployments registered for this model._

## Supply chain

_No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model's suppliers._

_Suppliers appear when verified with at least two strong sources. Sources are append-only; corrections add new sources rather than rewrite history._

## Common questions

### What is Maestro?

Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.

### Who makes Maestro?

Maestro is made by Moon Surgical, based in San Carlos, California, USA, founded in 2020.

### Where is Maestro deployed?

No verified deployments of Maestro are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

### What is Maestro's maturity stage?

Maestro is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.


## Sources (4)

1. https://www.prnewswire.com/news-releases/moon-surgical-second-fda-clearance-commercial-maestro
2. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K240598
3. https://www.biospace.com/moon-surgical-scopilot-fda-nvidia-holoscan
4. https://www.massdevice.com/moon-surgical-funding-fred-moll/

_API: GET /v1/models/d1fd6d55-bf1a-45e2-9612-d40019d2d867 · canonical URL: /models/moon-maestro_